Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Amgen Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 | 5 | 2 |
| Amgen Inc., Medical Equipment Deals By Type, 2010 to YTD 2016 | 7 | 1 |
| Amgen Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 | 8 | 1 |
| Amgen Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016 | 9 | 1 |
| Amgen Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 | 10 | 1 |
| Amgen Inc., Medical Equipment, Deal Details | 11 | 28 |
| Venture Financing | 11 | 1 |
| Gamida Cell Raises US$10 Million In Series E Financing | 11 | 2 |
| Partnerships | 13 | 1 |
| Exosome Diagnostics Enters into Agreement with Amgen | 13 | 1 |
| Flatiron Health Partners with Amgen | 14 | 1 |
| Biocartis Enters into Agreement with Amgen | 15 | 1 |
| Dako Enters into Co-Development Agreement with Amgen for Companion Diagnostic | 16 | 1 |
| Dako Enters Into Co-Development Agreement With Amgen For Molecular Diagnostic Test | 17 | 1 |
| Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test | 18 | 1 |
| KineMed Enters Into Co-Development Agreement With Amgen For Kinetic Biomarkers Of Brain Proteinopathies | 19 | 1 |
| Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test | 20 | 1 |
| Dako Enters Into Co-Development Agreement With Amgen | 21 | 1 |
| Dako Enters Into Co-Development Agreement With Amgen | 22 | 1 |
| Merger | 23 | 1 |
| AstraZeneca Rumored To Merge With Amgen | 23 | 1 |
| Amgen Enters into Licensing Agreement with Unilife | 24 | 1 |
| Debt Offering | 25 | 1 |
| Unilife Raises USD30 Million in First Tranche of Private Placement of 6% Senior Secured Convertible Notes Due 2023 | 25 | 2 |
| Amgen Raises USD850 Million in Public Offering of Notes Due 2017 | 27 | 2 |
| Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 | 29 | 2 |
| Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 | 31 | 2 |
| Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 | 33 | 2 |
| Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 | 35 | 2 |
| Acquisition | 37 | 1 |
| Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For US$401 Million | 37 | 2 |
| Amgen Inc. - Key Competitors | 39 | 1 |
| Key Employees | 40 | 2 |
| Locations And Subsidiaries | 42 | 6 |
| Head Office | 42 | 1 |
| Other Locations &Subsidiaries | 42 | 6 |
| Recent Developments | 48 | 1 |
| Strategy And Business Planning | 48 | 1 |
| Sep 11, 2015: AstraZeneca purchases US biologics manufacturing facility to support growing pipeline | 48 | 1 |
| Aug 24, 2015: Amgen opens new $300 million facility | 49 | 1 |
| May 28, 2015: Amgen and Caltech Establish Partnership in Health Sciences | 50 | 1 |
| Mar 24, 2015: Dako, an Agilent Technologies Company, Announces Expanded Collaboration with Amgen Within Companion Diagnostics | 51 | 1 |
| Mar 10, 2015: Amgen To Shut Down South San Francisco Facility | 52 | 1 |
| Financial Announcements | 53 | 1 |
| Jul 27, 2016: Amgen Reports Second Quarter 2016 Financial Results | 53 | 3 |
| Apr 28, 2016: Amgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90 | 56 | 2 |
| Jan 28, 2016: Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share Increased 19 Percent To $10.38 | 58 | 2 |
| Oct 28, 2015: Amgen's Third Quarter 2015 Revenues Increased 14 Percent To $5.7 Billion And Adjusted Earnings Per Share Increased 18 Percent To $2.72 | 60 | 3 |
| Jul 30, 2015: Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 | 63 | 2 |
| Apr 21, 2015: Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 | 65 | 2 |
| Jan 27, 2015: Amgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70 | 67 | 2 |
| Research And Development | 69 | 1 |
| Jan 12, 2015: Amgen and MD Anderson Announce Agreement to Develop BiTE Therapies for Myelodysplastic Syndrome | 69 | 1 |
| Corporate Communications | 70 | 1 |
| Oct 14, 2016: Amgen Announces Appointment Of Ellen J. Kullman To Board Of Directors | 70 | 1 |
| Jun 17, 2016: Amgen Appoints Esteban Santos Executive Vice President, Operations | 71 | 1 |
| Jul 30, 2015: Amgen Announces Appointment Of Fred Hassan To Board Of Directors | 72 | 1 |
| May 18, 2015: Amgen Appoints Jonathan P. Graham Senior Vice President, General Counsel And Secretary | 73 | 1 |
| Legal and Regulatory | 74 | 1 |
| Jul 20, 2016: Amgen Announces Settlement Of Securities Litigation | 74 | 1 |
| Other Significant Developments | 75 | 1 |
| Feb 12, 2016: West's Daikyo Crystal Zenith Cyclic Olefin Polymer Selected by Amgen | 75 | 1 |
| May 28, 2015: Amgen Launches Program To Further Advance Basic Biology Research | 76 | 1 |
| Mar 04, 2015: Amgen Announces 2015 Second Quarter Dividend | 77 | 1 |
| Appendix | 78 | 1 |
| Methodology | 78 | 1 |
| About GlobalData | 78 | 1 |
| Contact Us | 78 | 1 |
| Disclaimer | 78 | 1 |
